BRCA mutations and the risk of angiosarcoma after breast cancer treatment.
Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither therapeutic radiation nor clinically evident lymphedema. The absence of established risk factors led to speculation that the BRCA2 germline mutation could be a causative factor in the development of this patient's angiosarcoma. A literature review supported this concept.
West
John G
JG
Department of Surgery, The Breast Care and Imaging Center of Orange County, Orange, CA 92868, USA. jwest@breastcare.com
Weitzel
Jeffrey N
JN
Tao
May Lin
ML
Carpenter
Michele
M
West
Justin E
JE
Fanning
Caitlin
C
D000328:Adult; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000601:surgery*; D005260:Female; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006394:Hemangiosarcoma / Q000235:genetics*; D006801:Humans; D008408:Mastectomy; D009364:Neoplasm Recurrence, Local; D016609:Neoplasms, Second Primary / Q000235:genetics*; D012878:Skin Neoplasms / Q000235:genetics*
D024682:BRCA2 Protein